Last reviewed · How we verify

NCT05334134

COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children

Status unknown Last updated 19 April 2022
What this trial tests

trial in Multisystem Inflammatory Syndrome in Children in 300 participants. Status unknown.

Timeline
1 February 2020
Primary endpoint
31 December 2022
30 June 2023

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date1 February 2020
Primary completion31 December 2022
Estimated completion30 June 2023
Sites1 location across Denmark

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

Adults 1 Month to 17, any sex, with Multisystem Inflammatory Syndrome in Children or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study seeks to explore immunological mechanisms in patients with Multisystem Inflammatory Syndrome in Children (MIS-C) to improve the understanding of this pathogenesis of this disease. In a cohort of MIS-C patients diagnosed during the Wild type, Alpha, Delta and Omicron waves, research samples will be analyzed for whole-blood RNA expression, proteomics, inflammatory cytokines, cellular immune populations, autoantibodies, as well as host genetic markers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children.
    Nygaard U, Nielsen AB, Dungu KHS, Drici L, et al · · 2024 · cited 10× · PMID 38839859 · DOI 10.1038/s42003-024-06370-8

Verify or expand the search:

Other recruiting trials for Multisystem Inflammatory Syndrome in Children

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05334134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing